We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · February 01, 2021

Safety of ICI Rechallenge After Discontinuation for Immune-Related Adverse Events

Journal for immunotherapy of cancer


Additional Info

Journal for immunotherapy of cancer
Safety of Immune Checkpoint Inhibitor Rechallenge After Discontinuation for Grade ≥2 Immune-Related Adverse Events in Patients With Cancer
J Immunother Cancer 2020 Dec 21;8(2)e001622, M Allochery, T Lombard, M Martin, et al

Further Reading